[go: up one dir, main page]

ITRM20020255A1 - Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici. - Google Patents

Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.

Info

Publication number
ITRM20020255A1
ITRM20020255A1 IT2002RM000255A ITRM20020255A ITRM20020255A1 IT RM20020255 A1 ITRM20020255 A1 IT RM20020255A1 IT 2002RM000255 A IT2002RM000255 A IT 2002RM000255A IT RM20020255 A ITRM20020255 A IT RM20020255A IT RM20020255 A1 ITRM20020255 A1 IT RM20020255A1
Authority
IT
Italy
Prior art keywords
acid
salts
indolylpiruvic
therapeutic uses
alkali
Prior art date
Application number
IT2002RM000255A
Other languages
English (en)
Inventor
Vincenzo Politi
Andrea Margonelli
Antonio Sella
Barbara Bartolini
Francesca Somma
Cristina Corniello
Original Assignee
Polifarma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma Spa filed Critical Polifarma Spa
Priority to IT2002RM000255A priority Critical patent/ITRM20020255A1/it
Publication of ITRM20020255A0 publication Critical patent/ITRM20020255A0/it
Priority to AU2003233183A priority patent/AU2003233183A1/en
Priority to AT03727938T priority patent/ATE418334T1/de
Priority to JP2004503000A priority patent/JP2005529146A/ja
Priority to PCT/IT2003/000275 priority patent/WO2003094914A1/en
Priority to US10/513,859 priority patent/US20050208125A1/en
Priority to KR10-2004-7018015A priority patent/KR20040108787A/ko
Priority to EP03727938A priority patent/EP1501503B1/en
Priority to CA002483991A priority patent/CA2483991A1/en
Priority to DE60325468T priority patent/DE60325468D1/de
Priority to CN03810540A priority patent/CN100588398C/zh
Publication of ITRM20020255A1 publication Critical patent/ITRM20020255A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
IT2002RM000255A 2002-05-09 2002-05-09 Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici. ITRM20020255A1 (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IT2002RM000255A ITRM20020255A1 (it) 2002-05-09 2002-05-09 Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.
CN03810540A CN100588398C (zh) 2002-05-09 2003-05-07 用于治疗中枢神经系统紊乱的3-吲哚基丙酮酸的烯醇互变体基本纯的固体形式
PCT/IT2003/000275 WO2003094914A1 (en) 2002-05-09 2003-05-07 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
AT03727938T ATE418334T1 (de) 2002-05-09 2003-05-07 Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems
JP2004503000A JP2005529146A (ja) 2002-05-09 2003-05-07 中枢神経系障害の治療で使用するための実質的に純粋な固形型３−インドリルピルビン酸のエノール互変異性体
AU2003233183A AU2003233183A1 (en) 2002-05-09 2003-05-07 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
US10/513,859 US20050208125A1 (en) 2002-05-09 2003-05-07 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances
KR10-2004-7018015A KR20040108787A (ko) 2002-05-09 2003-05-07 중추 신경계 장애의 치료에 사용하기 위한 실질적으로순수한 고체 형태의 3-인돌릴피브르산의 에놀 토토머
EP03727938A EP1501503B1 (en) 2002-05-09 2003-05-07 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatment of central nervous system disturbances
CA002483991A CA2483991A1 (en) 2002-05-09 2003-05-07 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
DE60325468T DE60325468D1 (de) 2002-05-09 2003-05-07 Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000255A ITRM20020255A1 (it) 2002-05-09 2002-05-09 Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.

Publications (2)

Publication Number Publication Date
ITRM20020255A0 ITRM20020255A0 (it) 2002-05-09
ITRM20020255A1 true ITRM20020255A1 (it) 2003-11-10

Family

ID=11456293

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002RM000255A ITRM20020255A1 (it) 2002-05-09 2002-05-09 Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.

Country Status (11)

Country Link
US (1) US20050208125A1 (it)
EP (1) EP1501503B1 (it)
JP (1) JP2005529146A (it)
KR (1) KR20040108787A (it)
CN (1) CN100588398C (it)
AT (1) ATE418334T1 (it)
AU (1) AU2003233183A1 (it)
CA (1) CA2483991A1 (it)
DE (1) DE60325468D1 (it)
IT (1) ITRM20020255A1 (it)
WO (1) WO2003094914A1 (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012373A1 (en) * 2018-07-10 2020-01-16 Polindols S.R.L.S. New drugs chronic invalidating pathologies and to slow aging, based on a new metabolic tryptophan route and production process thereof
WO2021149806A1 (en) * 2020-01-24 2021-07-29 Morinaga Milk Industry Co., Ltd. Composition for improving neurite outgrowth
EP4200452A4 (en) 2020-08-18 2024-10-09 Enviro Metals, LLC METAL REFINING
CN115813919B (zh) * 2022-12-08 2024-02-06 佛山市妇幼保健院 吲哚-3-丙酮酸或其药用盐在制备治疗乳腺癌药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482844A (fr) * 1964-12-31 1967-06-02 Merck & Co Inc Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs
FR2306693A1 (fr) * 1975-04-11 1976-11-05 Roussel Uclaf Nouveaux derives du /9h/pyrido/3,4-b/ indole et leurs sels, procede de preparation et application a titre de medicaments
US4822812A (en) * 1987-05-21 1989-04-18 Merrell Dow Pharmaceuticals Inc. β-(Fluoromethylene)-5-hydroxytryptophan and derivatives and their use as prodrugs for MAO inhibition
IT1237472B (it) * 1989-10-04 1993-06-07 Polifarma Spa Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
TW288010B (it) * 1992-03-05 1996-10-11 Pfizer

Also Published As

Publication number Publication date
US20050208125A1 (en) 2005-09-22
EP1501503B1 (en) 2008-12-24
AU2003233183A1 (en) 2003-11-11
ATE418334T1 (de) 2009-01-15
CN1652773A (zh) 2005-08-10
WO2003094914A1 (en) 2003-11-20
JP2005529146A (ja) 2005-09-29
ITRM20020255A0 (it) 2002-05-09
EP1501503A1 (en) 2005-02-02
DE60325468D1 (de) 2009-02-05
CN100588398C (zh) 2010-02-10
CA2483991A1 (en) 2003-11-20
KR20040108787A (ko) 2004-12-24

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
NO20070249L (no) Pyrrazolo-pyrimidin derivater
BR0308461A (pt) Derivados de pirimidina
BR0308979A (pt) Derivados de indolilmaleimida
UY27181A1 (es) Derivados de xantina, su preparación y su empleo como medicamentos.
WO2003053922A3 (en) Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
UY28103A1 (es) Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
CY1109055T1 (el) 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
DK1125907T3 (da) Mellemprodukter til fremstilling af citalopram
ATE530531T1 (de) Verfahren zur herstellung von bosentan
PA8516901A1 (es) "5-cloro-3-(4-metansulfonilfenilo)-6'-metil-[2,3'] bipiridinil o en forma cristalina pura y proceso para la síntesis"
ATE280767T1 (de) Antidiabetische thiazolidindione und ihre herstellung
ATE496056T1 (de) Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
CY1108156T1 (el) Στερεοεκλεκτικη συνθεση αναλογων βιταμινης d
ITRM20020255A1 (it) Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.
NO20010265L (no) 3-(1-hydroksy-pentyliden)-5-nitro-3H-benzofuran-2-on, fremgangsmåte for fremstilling og anvendelse derav
DE602004025935D1 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung
ITMI20020933A1 (it) Procedimento per la sintesi di clopidogrel
ATE411299T1 (de) Chlorsubstituierte guanidine
DE60009032D1 (de) Benzolsulfonamid-derivate und ihre verwendung
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren
EP1555257A4 (en) PROCESS FOR PREPARING AN AROMATIC NITRIL COMPOUND